Bioabsorbable mesh use in midline abdominal wall prophylaxis and repair achieving fascial closure: a cross-sectional review of stage of innovation by Smart, Neil J. & Daniels, Ian R.
Vol.:(0123456789) 
Hernia 
https://doi.org/10.1007/s10029-020-02217-3
REVIEW
Bioabsorbable mesh use in midline abdominal wall prophylaxis 
and repair achieving fascial closure: a cross‑sectional review of stage 
of innovation
S. K. Kamarajah1,2  · N. J. Smart3 · I. R. Daniels3 · T. D. Pinkney4 · R. L. Harries5
Received: 22 March 2020 / Accepted: 11 May 2020 
© The Author(s) 2020
Abstract
Background Achieving stable closure of complex or contaminated abdominal wall incisions remains challenging. This study 
aimed to characterise the stage of innovation for bioabsorbable mesh devices used during both midline closure prophylaxis 
and complex abdominal wall reconstruction and to evaluate the quality of current evidence.
Methods A systematic review of published and ongoing studies was performed until 31st December 2019. Inclusion criteria 
were studies where bioabsorbable mesh was used to support fascial closure either prophylactically after midline laparotomy 
or for repair of incisional hernia with midline incision. Exclusion criteria were: (1) study design was a systematic review, 
meta-analysis, letter, review, comment, or conference abstract; (2) included less than p patients; (3) only evaluated biologi-
cal, synthetic or composite meshes. The primary outcome measure was the IDEAL framework stage of innovation. The key 
secondary outcome measure was the risk of bias in non-randomised studies of interventions (ROBINS-I) criteria for study 
quality.
Results Twelve studies including 1287 patients were included. Three studies considered mesh prophylaxis and nine studies 
considered hernia repair. There were only two published studies of IDEAL 2B. The remainder was IDEAL 2A studies. The 
quality of the evidence was categorised as having a risk of bias of a moderate, serious or critical level in nine of the twelve 
included studies using the ROBINS-I tool.
Conclusion The evidence base for bioabsorbable mesh is limited. Better reporting and quality control of surgical techniques 
are needed. Although new trial results over the next decade will improve the evidence base, more trials in emergency and 
contaminated settings are required to establish the limits of indication.
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Introduction
Incisional hernias occur commonly after midline abdomi-
nal surgery, with a reported incidence of 12.8% at 2 years 
follow-up in a systematic review of 14,618 patients [1]. Inci-
sional hernias can result in a reduced quality of life, carry 
a risk of strangulation, and present a significant financial 
burden for the health service [2].
There has been significant interest in both the prevention 
and repair of incisional hernia with the use of mesh. In 2010, 
the Ventral Hernia Working Group (VHWG) recommended 
against the use of permanent synthetic mesh for both Grade 
3 and Grade 4 ventral hernias (contaminated or infected) 
and suggested that there was an increased risk of surgical 
site occurrence with the use of permanent synthetic mesh 
in Grade 2 ventral hernias (co-morbid e.g. smoker, obese, 
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diabetic, immunocompromised), and, therefore, the choice 
of biological mesh may pose an advantage in such cases [3]. 
However, in recent years, there has been the development 
of bioabsorbable meshes (delayed absorbable synthetic) as 
a possible cost-effective alternative to biological meshes. In 
clinical practice, mesh choice can pose a dilemma to the sur-
geon; balancing both the advantage of recurrence prevention 
against the risk of mesh complications for the patient, whilst 
also considering the cost implications for the health service.
This review aimed to determine the quality and stage of 
innovation of the evidence supporting the use of bioabsorb-
able mesh in both prophylaxis after midline fascial closure 
and during abdominal wall reconstruction with primary mid-
line fascial closure.
Methods
Search strategy
A systematic search of PubMed, EMBASE, and the 
Cochrane Library until 31st December 2019 was performed 
by two independent investigators (SKK, RH). The Clinical-
Trials.gov database was also queried for ongoing studies. 
The search terms used were “biosynthetic mesh” or “bioab-
sorbable mesh”, and “ventral hernia”, “incisional hernia,” or 
“abdominal wall reconstruction”, individually or in combi-
nation. The “related articles’’ function was used to broaden 
the search, and all citations were considered for relevance. A 
manual search of reference lists in recent reviews and eligi-
ble studies was also undertaken. This manuscript is reported 
according to the preferred reporting items for systematic 
reviews and meta-analysis (PRISMA) [4] and assessing the 
methodological quality of systematic reviews (AMSTAR-2) 
[5] guidelines. This study was prospectively registered with 
the PROSPERO database (Registration CRD42020160307).
Inclusion/exclusion criteria
Studies were included according to the following criteria: (1) 
evaluated use of a bioabsorbable mesh to support primary 
fascial closure of midline abdominal wounds or repair of 
incisional hernia with midline incision; (2) study design was 
a randomized controlled trial (RCT), prospective observa-
tional study, retrospective cohort study, or case series; (3) 
only included patients aged 16 years and older; (4) articles 
published in English only. Studies were excluded according 
to the following criteria: (1) study design was a systematic 
review, meta-analysis, letter, review, comment, or confer-
ence abstract; (2) included less than three patients; (3) only 
evaluated biological, synthetic, or composite meshes.
Study outcome measures
The primary outcome measure was the stage of innovation, 
according to the idea, development, exploration, assessment, 
long-term follow-up (IDEAL) framework [6]. The level of 
evidence in the IDEAL staging system were 1 (case series 
with high risk of bias), 2A (prospective development study), 
2B (research database; explanatory or feasibility RCT; pro-
spective exploration study), 3 (RCT), and 4 (high-quality 
prospective registries with long-term monitoring and low 
risk of bias). All assessments within this study were carried 
out independently by two authors (SKK and RLH) and disa-
greement was resolved by re-examining the relevant article 
until consensus was achieved (NJS).
Secondary outcome measures
One secondary outcome measure was the quality of evidence 
assessed using the risk of bias in non-randomised studies of 
interventions (ROBINS-I) [7]. The ROBINS-I views each 
study as an attempt to emulate (mimic) a hypothetical prag-
matic randomised trial and covers seven distinct domains 
through which bias might be introduced. These domains are 
divided according to pre-intervention (bias due to confound-
ing and bias in selection of participants into the study), at 
intervention (bias in classification of interventions), and 
post-intervention (bias due to deviations from intended 
interventions, bias due to missing data, bias in measurement 
of outcomes, and bias in selection of the reported result). 
Each of these seven domains is graded according to low, 
moderate, critical, serious or no information. The other sec-
ondary outcome measures of interest were the number of 
studies reporting (1) outcomes according to the European 
Hernia Society (EHS) consensus statement [8], (2) method-
ology reported according to strengthening the reporting of 
cohort studies in surgery (STROCCS) [9] for observational 
studies or consolidated standards of reporting trials (CON-
SORT) [10] for randomised clinical trials (3) incidence of 
incisional hernia (in prophylaxis studies) or recurrence (in 
hernia repair studies), (4) surgical site infection (SSI) rate, 
(5) seroma rate, and (6) mesh explantation rate.
Data extraction
Patient demographics, indications, and type of bioabsorb-
able mesh used were extracted. Studies were grouped into 
those examining prophylactic placement in primary clo-
sure of laparotomy only (‘prophylaxis’), repair of inci-
sional hernia/complex abdominal wall reconstruction only 
(‘repair’) or reporting both (‘mixed’). Descriptions of 
procedures performed were collected including surgical 
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technique, number of procedures previously performed 
by the surgeon and monitoring of technique. Degree of 
contamination (clean contaminated, contaminated, and 
dirty surgery) was defined according to the Centre for 
Disease Control Surgical Wounds Classification [11] 
and location of bioabsorbable mesh placement was also 
evaluated: intraperitoneal, preperitoneal, retro-muscular, 
retro-rectus, inlay, or onlay [12, 13]. Urgency of surgery 
(i.e. elective and emergency) was also extracted from each 
study.
Statistical analysis
We pre-planned our analysis to be primarily descriptive in 
nature. We did not predict the need for modelling or mul-
tivariable analyses. Event rates are reported as percent-
ages (%). Continuous variables were tested for normality. 
Normal data were presented as mean and non-normal data 
as median with interquartile range.
Results
From 1609 studies short-listed, 12 full-text articles met the 
inclusion criteria (Fig. 1). Of these, three (25%) examined 
bioabsorbable mesh for prophylaxis [14–16] and nine (75%) 
reported repair after incisional hernia/abdominal wall recon-
struction [17–25]. Studies for prophylaxis included a total of 
201 patients with a median follow-up of 11 months (range 
9–24 months) and those for repair included 1086 patients 
with a median follow-up of 23 months (range 1–26 months).
Tables 1 and 2 summarises the characteristics of the 
included studies. Gore-BioA® (WL Gore, Arizona, USA) 
was the most used mesh for prophylaxis of the abdomi-
nal wall used in two studies [15, 16], followed by TIGR® 
(Novus Scientific, Uppsala, Sweden) in one study [14]. 
In papers reporting bioabsorbable mesh for repair only, 
Phasix™ (BD Bard, Rhode Island, USA) [18, 19, 24, 25] 
was the most commonly reported followed by Gore-BioA® 
(n = 3) [20, 22, 23]. One study [21] reported use of Phasix™, 
TIGR®, Gore-BioA®, and another study [17] did not report 
type of bioabsorbable mesh used.
Fig. 1  PRISMA diagram of 
inclusion and exclusion of 
studies
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IDEAL stage of innovation and ROBINS‑I quality 
of evidence
Distribution of IDEAL stage and ROBINS-I of included 
studies are presented in Tables 3 and 4 respectively. From the 
three prophylaxis studies, two [14, 16] evaluated bioabsorba-
ble mesh following midline laparotomy and one [15] follow-
ing prophylactic reinforcement of abdominal wall donor site 
after breast reconstruction. Of these three studies, one study 
[15] included elective patients and another included both 
elective and emergency patients [16]. Another study [14] 
did not report surgical urgency of these included patients. 
The degrees of contamination were only reported in the 
one study [16]. Gore-BioA® was used in two studies with 
a retro-rectus placement [15, 16]. The other used TIGR™ 
in an onlay placement [14]. Two studies were IDEAL stage 
2A [14, 15] and one was IDEAL stage 2B [16]. None of the 
included studies of prophylaxis were reported according to 
the STROCCS statement for observational studies.
From nine studies of repair, seven studies reported only 
elective patients undergoing repair of ventral hernia and 
two studies for abdominal wall reconstruction. The degree 
of contamination was reported in seven studies, [19–25] of 
which one study [24] was Centre for Centers for Disease 
Control and Prevention (CDC) Class I and the rest included 
a mixture of CDC Class II–IV procedures. Mesh place-
ment was reported as retro-rectus in four studies [19, 22, 
23, 25] and a combination in five studies [18, 20–22, 24]. 
Eight studies [17–19, 21–25] were IDEAL Stage 2A and one 
[20] was IDEAL Stage 2B. None reported standardisation of 
Table 1  Patient characteristics of included studies
ASA American Society of Anesthsiologists, BMI body mass index, CVD cardiovascular disease, COPD chronic obstructive pulmonary disease, 
HTN hypertension, IQR interquartile range, n numbers, NR not reported, PCS prospective cohort study, RCT randomised controlled trial, RCS 
retrospective cohort study, SD standard deviation
*Refers to patients in the mesh group only
**Reported as 40% for CVD and hypertension combined
***No baseline patient characteristics reported for bioabsorbable mesh
# Where indicated, data presented as mean and standard deviation
Study name Study design Median (IQR) 
or mean (SD) 
Age, years
Patients, n Patients with 
bioabsorbable 
mesh, n
Male, % Median (IQR) 
or mean (SD) 
BMI kg/m2
Smokers, %* Diabetes, %* COPD, %*
Prophylaxis
 Soderback 
(2016) [14]
PCS 65.0 (53.5–
67.5)
16 16 31 NR 38 6 13
 Jordan 
(2018) [15]
RCS 50.4 (± 9.3)# 87 65 0 29.5 (± 5.4)# 5 9 NR
 Pizza (2019) 
[16]
RCT 58.0 (29.0–
88.0)
100 50 NR 28.0 (17.0–
35.0)
26 16 30
Repair
 Cobb 
(2015)*** 
[17]
RCS NR 255 35 NR 32.2 (15.0–
66.6)
NR NR NR
 Buell (2016) 
[18]
RCS 56.9 73 31 74 29.9 3 26 NR
 Plymale 
(2017) [19]
PCS 52.0 (44.0–
62.0)
31 31 45 33.0 (28.6–
38.4)
23 26 29
 Rosen (2017) 
[20]
PCS 58.0 (27.0–
91.0)
104 104 40 28.0 (17.0–
40.0)
19 18 11
 Sahoo (2017) 
[21]
PCS 61.0 (51.0–
70.0)
232 58 NR 31.0 (27.0–
38.0)
7 24 NR
 Cho (2018) 
[22]
RCS 56.5 (± 11.7)# 81 81 33 34.9 (± 8.4)# 11 28 NR
 Garcia-Urena 
(2018) [23]
PCS 60.9 (32.0–
86.0)
169 169 59 30.7 (20.3–
46.9)
36 31 16
 Roth (2018) 
[24]
PCS 54.7 (± 12.0)# 121 121 38 32.2 (± 4.5)# 23 33 28
 Pakula 
(2019) [25]
RCS 47.0 (± 13.0)# 20 20 50 35.0 (± 7.4)# NR 35 NR
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Table 2  Summary of surgery and mesh characteristics (arranged chronologically by indication)
Study name Study coun-
try
Type of bio-
absorbable 
mesh
Mesh place-
ment
Fascial 
closure 
suture and 
technique
Hernia size, 
 cm2
CDC class
Grade I, % Grade II, % Grade III, % Grade V, %
Prophylaxis
 Soderback 
(2016) 
[14]
Sweden TIGR® Onlay Continuous 
PDS®
NA NR NR NR NR
 Jordan 
(2018) 
[15]
USA Gore Bio-A® Retro-rectus Interrupted NA NR NR NR NR
 Pizza 
(2019) 
[16]
Italy Gore Bio-A® Retro-rectus Continuous 
PDS® 
(post 
sheath)
Continuous 
PDS® (ant 
sheath)
NA 0 56 44 0
Repair
 Cobb 
(2015) 
[17]
USA NR Retro-rectus Continuous 
2/0 PDS® 
(post 
sheath)
0 PDS® (ant 
sheath)
NR* 1 NR*** NR*** NR***
 Buell 
(2016) 
[18]
USA Phasix™ Mixed NR NR NR NR NR NR
 Plymale 
(2017) 
[19]
USA Phasix™ Retro-rectus Absorb-
able (post 
sheath)
PDS® (ant 
sheath)
105 (74–130) 97 3 0 0
 Rosen 
(2017) 
[20]
USA Gore Bio-A® Mixed NR 137 (10–513) 0 23 77 0
 Sahoo 
(2017) 
[21]
USA Gore 
Bio-A®, 
Phasix™, 
TIGR®
Mixed NR 10 (7–15) 0 59 41 0
 Cho (2018) 
[22]
USA Gore Bio-A® Mixed 
(Retro-rec-
tus versus 
intraperito-
neal)
Continuous 
0 PDS® 
(post 
sheath) 
Continuous 
1 PDS® 
(ant sheath)
148 (± 123) 68 17 1 14
 Garcia-
Urena 
(2018) 
[23]
Spain Gore Bio-
A®**
Retro-rectus Continuous 
absorbable 
monofila-
ment (post 
sheath)
PDS® (ant 
sheath)
447 (240–
1380)
85 7 7 2
 Roth (2018) 
[24]
USA Phasix™ Mixed NR 116 (± 81) 100 0 0 0
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technique or location of bioabsorbable mesh placement; the 
choice of mesh type was based on the preference of operat-
ing surgeon. None of the included studies of repair were 
reported according to the STROCCS statement for obser-
vational studies.
Outcome reporting
None of the studies in this review have reported outcomes 
according to the European Hernia Society (EHS) consen-
sus statement [8]. Only one study reported ‘freedom of 
recurrence’ survival times [14]. In the prophylaxis group 
(which included three studies), one study reported a defini-
tion used for detection of incisional hernia, which included 
a combination of clinical examination and radiologi-
cal assessment with ultrasound [12]. In the repair group 
(which included nine studies), five reported a definition 
for recurrence of hernia (clinical only [14, 19], clinical 
combined with computed tomography (CT) [15, 17], and 
clinical combined with either CT or magnetic resonance 
imaging [20]). In the prophylaxis group, the rate of inci-
sional hernia was 12.2% (16/131) at a median follow-up 
of 24 months, whereas in the repair group, the rate of 
recurrence was 7.7% (43/557) with a median follow-up 
of 22 months.
Outcome reporting per study is described in Table 5. 
SSI rates were reported in two of three studies from the 
prophylaxis group, and seven of the nine studies in the 
repair group. The SSI rate was 1.5% (4/66) and 12.2% 
(71/584) for the prophylaxis and repair studies, respec-
tively. Seroma rates were reported in two prophylaxis stud-
ies and six repair studies. The seroma rate was 4.5% (3/66) 
and 9.3% (47/503) for the prophylaxis and repair stud-
ies, respectively. Mesh explantation rates were reported 
in three prophylaxis studies and five repair studies. The 
mesh explantation rate was 0% (0/131) and 0.7% (3/443) 
for the prophylaxis and repair studies, respectively.
Reporting of surgical technique
Of the 12 studies, 9 studies (75%) provided details of sur-
gical procedure; all three studies from the prophylaxis 
group and six from the repair group. None of the papers 
reported the minimum number of procedures performed 
by the operating surgeons as a requirement. Suture choice 
was described in seven of the studies [14, 16, 17, 19, 22, 
23, 25] (Table 2), however only one study described needle 
size used [16]. Fascial closure technique (continuous or 
interrupted) was described in seven of the studies [14–17, 
22, 23, 25]; however, no studies mentioned suture bite size 
utilised (e.g. small bite versus large bite), and only two 
study stated that a suture length: wound length (SL:WL) 
ratio of > 4:1 was used; however, it was not formally 
recorded [14, 16].
NA not applicable, NR not reported, PDS polydioxanone, USA United States of America
*Hernia size and median follow-up not reported specifically for those who had bioabsorbable mesh
**Combined use with a polypropylene mesh
***Reported as CDC Class II–V = 33
Table 2  (continued)
Study name Study coun-
try
Type of bio-
absorbable 
mesh
Mesh place-
ment
Fascial 
closure 
suture and 
technique
Hernia size, 
 cm2
CDC class
Grade I, % Grade II, % Grade III, % Grade V, %
 Pakula 
(2019) 
[25]
USA Phasix™ Retro-rectus Continuous 
2/0 PDS® 
(post 
sheath) 0 
Prolene® 
or PDS® 
(ant sheath)
533 (± 500) 35 25 40 0
Table 3  Distribution of IDEAL stage of innovation, shown by indica-
tion
Indication IDEAL stage
1 (Case 
report)
2A 
(Cohort 
study)
2B (Feasi-
bility RCT/
research 
database/
prospective 
exploration 
study)
3 (RCT) 4 (Registry)
Prophy-
laxis
0 2 1 0 0
Repair 0 8 1 0 0
Total 0 10 2 0 0
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Table 4  Distribution of ROBINS-I of study quality, shown by indication
Study name Baseline con-
founding
Selection of 
participants
Classification 
of interven-
tions
Deviation 
from intended 
interventions
Missing data Measurement 
of outcomes
Selection 
of reported 
results
Overall risk of 
bias
Prophylaxis
 Soderback 
(2016) [14]
Critical Moderate Serious NI Low Moderate Moderate Critical
 Jordan (2018) 
[15]
Serious Moderate Moderate NI Low Moderate Moderate Moderate
 Pizza (2019) 
[16]
Low Low Low Low Low Moderate Low Low
Repair
 Cobb (2015) 
[17]
Serious Serious Moderate NI Low Moderate Low Moderate
 Buell (2016) 
[18]
Critical Moderate Critical NI Moderate Moderate Moderate Moderate
 Plymale 
(2017) [19]
Serious Moderate Moderate NI Low Moderate Moderate Moderate
 Rosen (2017) 
[20]
Moderate Moderate Low NI Low Low Moderate Low
 Sahoo (2017) 
[21]
Low Low Low NI Low Low Low Low
 Cho (2018) 
[22]
Critical Moderate Low NI Moderate Moderate Low Moderate
 Garcia-Urena 
(2018) [23]
Moderate Moderate Low NI Low Low Moderate Moderate
 Roth (2018) 
[24]
Critical Moderate Moderate NI Low Moderate Moderate Moderate
 Pakula 
(2019) [25]
Serious Critical Critical NI Low Moderate Moderate Serious
Table 5  Incidence of post-operative outcomes
*Outcomes not reported specifically for those who had bioabsorbable mesh
Study name Patients with 
bioabsorbable 
mesh, n
Type of bioabsorbable mesh Incisional hernia 
or recurrence, %
SSI, % Seroma, % Mesh 
explanta-
tion, %
Median 
follow-up, 
months
Prophylaxis
 Soderback (2016) [14] 16 TIGR® 0 6.3 6.3 0 9
 Jordan (2018) [15] 65 Gore-BioA® 20.0 NR NR 0 11
 Pizza (2019) [16] 50 Gore-BioA® 6.0 6.0 4.0 0 24
Repair
 Cobb (2015) [17] 35 NR 17.1 NR* NR* NR* 17
 Buell (2016) [18] 31 Phasix™ 6.5 NR NR NR NR
 Plymale (2017) [19] 31 Phasix™ 0 0 12.9 0 24
 Rosen (2017) [20] 104 Gore-BioA™ 16.6 19.8 6.2 1.0 NR
 Sahoo (2017) [21] 58 Gore-BioA®, Phasix™, 
TIGR®
NR 22.4 1.7 1.7 22
 Cho (2018) [22] 81 Gore-BioA® 11.1 6.2 NR 0 24
 Garcia-Urena (2018) [23] 169 Gore-BioA®** 2.9 12.4 19.5 0.6 26
 Roth (2018) [24] 121 Phasix™ 9.0 9.0 6.0 NR NR
 Pakula (2019) [25] 20 Phasix™ 0 10.0 10.0 NR 21
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Discussion
This systematic review found that the evidence base for the 
use of bioabsorbable mesh in both prophylaxis following 
midline closure and repair of ventral hernias is limited. 
Most of the included studies were IDEAL stage 2A, with 
only two studies of IDEAL Stage 2B. The quality of the 
evidence was categorised as having a risk of bias of a 
moderate, serious or critical level in nine of the twelve 
included studies using the ROBINS-I tool.
In the included prophylaxis studies, the incisional her-
nia rate was found to be 12.2%, with a seroma rate of 
4.5%. When examining the role of bioabsorbable mesh in 
prophylaxis, it should be compared to synthetic mesh. The 
EHS guidelines [26], published in 2015, made a weak rec-
ommendation in favour of prophylactic mesh augmentation 
in elective midline laparotomy in high-risk patients to pre-
vent incisional hernia formation; however, could not make 
any recommendation about mesh position, fixation or mesh 
type due to lack of evidence. Since then, a meta-analysis 
of RCTs [27] demonstrated synthetic mesh had a signifi-
cantly lower rates of incisional hernia (4.2% vs. 28.3%, 
p < 0.001) than the suture group, but higher seroma rates 
(14.6% vs. 8.9%, p = 0.04). Whilst the evidence to support 
the use of bioabsorbable mesh in prophylaxis is limited, it 
may be that it has a role in a sub-group of patients when 
wanting to avoid seroma formation, accepting a potentially 
higher rate of hernia formation. However, more research 
is required to determine this further.
Adequate length of follow-up for detection of long-term 
outcomes such as recurrence is critical when conducting 
mesh related studies. The included studies had median fol-
low-up durations of 11 months (range 9–24 months) and 
22 months (range 1–24 months) for prophylaxis and repair, 
respectively. Previous work has shown that the prevalence 
of incisional hernias after midline incisions was 12.8% 
at a weighted mean of 23.7 months [1], and, therefore, 
follow-up shorter than 2 years in abdominal wall studies is 
likely to underestimate the recurrence rate. The incidence 
of hernia recurrence in the repair group was 7.7% (range 
0–17.0%), which is lower than expected. The reasons for 
this may in part be explained by the fact that three of the 
studies failed to report length of follow-up [18, 20, 24], 
a further study did not report recurrence rate, was report-
ing 30-day outcomes only [21] and five studies failed to 
report a definition for hernia recurrence detection [14, 15, 
17, 19, 20]. Similarly, in the prophylaxis group, one study 
investigated endpoints of dehiscence, SSI, seroma, and 
pain only [14].
In 2013, the European Hernia Society (EHS) pub-
lished recommendations for reporting outcomes results 
in abdominal wall repair research [8]. This included the 
reporting of the surgical technique, mesh placement and 
fixation method, hernia size, method of follow-up, and 
detection method of recurrence. It also recommended a 
preferred method to report the outcome of recurrence of 
time to event analysis using Kaplan–Meier estimates of 
‘freedom of recurrence’. Few of the included studies met 
these criteria for reporting outcomes. Two repair studies 
failed to describe the median hernia size [16, 22]. There 
were differences in the detection of recurrence methods 
employed (clinical versus radiological (ultrasound versus 
cross-sectional imaging e.g. computed tomography) versus 
combination), although five studies failed to describe the 
detection method used [11, 13, 16, 18, 22]. Several stud-
ies included a mixture of mesh placements within their 
cohorts making it difficult to draw meaningful conclusions 
from the results. Only one study reported the outcome of 
recurrence using ’freedom of recurrence’ survival curves 
[14].
We have examined all studies using a range of different 
bioabsorbable meshes. It should be noted that each consist 
of different scaffold fibres which equate to differences in 
their absorption time. Gore Bio-A® consists of Polyglycolic 
acid and trimethylene carbonate and is resorbed within 6–7 
months [28]. Phasix™ consists of poly-4-hydroxybutyrate 
(P4HB) and is resorbed within 12 months [29]. TIGR® con-
sists of a fast-degrading copolymer between glycolide and 
trimethylene carbonate and a slow-degrading copolymer 
between lactic and trimethylene carbonate [30]. The fast-
degrading copolymer is absorbed by 4 months, whereas the 
slow-degrading copolymer loses strength after 6–9 months 
and is completely resorbed at 3 years. Clearly, the differ-
ences in absorption time may equate to differences in out-
comes such as hernia occurrence/recurrence.
Current ongoing work investigating the role of bioab-
sorbable mesh in abdominal wall surgery includes four 
observational studies and two randomised controlled trials 
registered on trials registries. A multicentre observational 
study (NCT04132986) of bioabsorbable mesh in contami-
nated ventral hernia repairs is currently recruiting in France 
and aiming to recruit 200 patients [31]. The ATLAS trial 
(NCT02712398) is a prospective multicentre observational 
study assessing the use of Phasix™ in at-risk patients (one 
or more co-morbidities) having a laparoscopic ventral or 
incisional hernia repair, aiming to recruit 120 partici-
pants [32]. Two further multicentre observational studies 
(NCT01961687 [33] and NCT02720042 [34]) are assessing 
the role of Phasix™ for ventral or incisional hernia repair. 
The PREBIOUS trial (NCT02208557) is a multicentre 
randomised controlled trial of prophylaxis in midline lap-
arotomy closure with a bioabsorbable mesh versus suture 
closure only and is also currently recruiting [35]. A further 
study is randomising at-risk patients to either biological 
[Strattice™ (Allergan, Dublin, Ireland)] or bioabsorbable 
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(Gore Bio-A®) mesh during ventral hernia repair in those 
with VHWG Grade 2 or Grade 3 (NCT01794338) [36]; this 
study is of particular interest as it directly compares bio-
absorbable to biological mesh for use in repair in at-risk 
patient, which is likely where bioabsorbable mesh would 
have a key role, if outcomes are similar, due to a potential 
cost saving. It is hoped that the results of these ongoing 
studies will add to the evidence base, addressing some of 
the deficits in the evidence to date.
There are limitations of this study, the use of IDEAL 
collaboration grading can be subjective [5]; however, this 
was mitigated by assessment by two independent asses-
sors. It also categorises research databases, feasibility non-
randomised studies alongside randomised feasibility and 
pilot studies and are linked by their aims and purpose rather 
than study design, which could be viewed as a weakness. 
ROBINS-I is a tool focusing specifically on risk of bias in 
non-randomised trials [6] and is, therefore, not the optimal 
test to assess bias risk in the included feasibility RCT [12].
In summary, the evidence base for the use of bioabsorb-
able mesh is limited for both the prophylaxis of midline 
closure and the repair of abdominal wall hernias. Further 
studies investigating the use of bioabsorbable mesh in 
abdominal wall surgery are currently ongoing. Future work 
should report according to the European Hernia Society 
(EHS) published recommendations for reporting outcomes 
results in abdominal wall repair research [7].
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